Bone Matrix Proteoglycans in Skeletal Function - Osteogenesis Imperfecta - page 87

[90] Nugent MA, Iozzo RV. Fibroblast growth factor-2. Int J
Biochem Cell Biol 2000;32(2):115-20.
[91] Aviezer D, Hecht D, Safran M, Eisinger M, David G, Yayon A.
Perlecan, basal lamina proteoglycan, promotes basic ibroblast
growth factor-receptor binding, mitogenesis, and angiogenesis.
Cell 1994;79(6):1005-13.
[92] DeCarlo AA, Whitelock JM. The role of heparan sulfate
and perlecan in bone-regenerative procedures. J Dent Res
2006;85(2):122-32.
[93] Arikawa-Hirasawa E, Watanabe H, Takami H, Hassell JR,
Yamada Y. Perlecan is essential for cartilage and cephalic
development. Nat Genet 1999;23(3):354-8.
[94] Costell M, Gustafsson E, Aszodi A, Morgelin M, Bloch W,
Hunziker E, et al. Perlecan maintains the integrity of cartilage
and some basement membranes. J Cell Biol 1999;147(5):1109-22.
[95] Nicole S, Davoine CS, Topaloglu H, Cattolico L, Barral D,
Beighton P, et al. Perlecan, the major proteoglycan of base-
ment membranes, is altered in patients with Schwartz-
Jampel syndrome (chondrodystrophic myotonia). Nat Genet
2000;26(4):480-3.
[96] Arikawa-Hirasawa E, Wilcox WR, Le AH, Silverman N,
Govindraj P, Hassell JR, et al. Dyssegmental dysplasia,
Silverman-Handmaker type, is caused by functional null
mutations of the perlecan gene. Nat Genet 2001;27(4):431-4.
[97] Woods A. Syndecans: transmembrane modulators of adhesion
and matrix assembly. J Clin Invest 2001;107(8):935-41.
[98] Carey DJ. Syndecans: multifunctional cell-surface co-receptors.
Biochem J 1997;327( Pt 1 ):1-16.
[99] Bernield M, Kokenyesi R, Kato M, Hinkes MT, Spring J,
Gallo RL, et al. Biology of the syndecans: a family of trans-
membrane heparan sulfate proteoglycans. Annu Rev Cell Biol
1992;8:365-93.

for the functions of syndecan-2 and syndecan-4. J Biol Chem
2005;280(52):42573-79.

[109] David G, Bai XM, Van der Schueren B, Marynen P, Cassiman JJ,

Van den Berghe H. Spatial and temporal changes in the expres-
sion of ibroglycan (syndecan-2) during mouse embryonic
development. Development 1993;119(3):841-54.

[110] Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS,

Luthy R, et al. Osteoprotegerin: a novel secreted protein involved
in the regulation of bone density. Cell 1997;89(2):309-19.

[111] Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E,

Morinaga T, et al. Characterization of structural domains
of human osteoclastogenesis inhibitory factor. J Biol Chem
1998;273(9):5117-23.

[112] Standal T, Seidel C, Hjertner O, Plesner T, Sanderson RD,

Waage A, et al. Osteoprotegerin is bound, internalized, and
degraded by multiple myeloma cells. Blood 2002;100(8):3002-7.

[113] Mosheimer BA, Kaneider NC, Feistritzer C, Djanani AM, Sturn

DH, Patsch JR, et al. Syndecan-1 is involved in osteoprotegerin-
induced chemotaxis in human peripheral blood monocytes.
J Clin Endocrinol Metab 2005;90(5):2964-71.

[114] Molteni A, Modrowski D, Hott M, Marie PJ. Differential

expression of ibroblast growth factor receptor-1, -2, and -3
and syndecan-1, -2, and -4 in neonatal rat mandibular condyle
and calvaria during osteogenic differentiation in vitro. Bone
1999;24(4):337-47.

[115] Modrowski D, Orosco A, Thevenard J, Fromigue O, Marie PJ.

Syndecan-2 overexpression induces osteosarcoma cell apop-
tosis: implication of syndecan-2 cytoplasmic domain and JNK
signaling. Bone 2005;37(2):180-9.

[116] Paciici M, Shimo T, Gentili C, Kirsch T, Freeman TA, Enomoto-

Iwamoto M, et al. Syndecan-3: a cell-surface heparan sulfate
proteoglycan important for chondrocyte proliferation and
function during limb skeletogenesis. J Bone Miner Metab
2005;23(3):191-9.

[100] Kim CW, Goldberger OA, Gallo RL, Bernield M. Members

of the syndecan family of heparan sulfate proteoglycans are
expressed in distinct cell-, tissue-, and development-speciic
patterns. Mol Biol Cell 1994;5(7):797-805.

[117] Kosher RA. Syndecan-3 in limb skeletal development. Microsc

Res Tech 1998;43(2):123-30.

[101] De Luca M, Klimentidis YC, Casazza K, Chambers MM, Cho R,

Harbison ST, et al. A conserved role for syndecan family mem-
bers in the regulation of whole-body energy metabolism. PloS
One 2010;5(6):e11286.

[118] Dealy CN, Seghatoleslami MR, Ferrari D, Kosher RA. FGF-

stimulated outgrowth and proliferation of limb mesoderm is
dependent on syndecan-3. Dev Biol 1997;184(2):343-50.

[119] Echtermeyer F, Bertrand J, Dreier R, Meinecke I, Neugebauer

K, Fuerst M, et al. Syndecan-4 regulates ADAMTS-5 acti-
vation and cartilage breakdown in osteoarthritis. Nat Med
2009;15(9):1072-6.

[102] Sanderson RD, Sneed TB, Young LA, Sullivan GL, Lander

AD. Adhesion of B lymphoid (MPC-11) cells to type I collagen
is mediated by integral membrane proteoglycan, syndecan.
J Immunol 1992;148(12):3902-11. [120] Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise.

J Clin Invest 2001;108(4):497-501. [103] Germeyer A, Klinkert MS, Huppertz AG, Clausmeyer S,

Popovici RM, Strowitzki T, et al. Expression of syndecans, cell-
cell interaction regulating heparan sulfate proteoglycans, within
the human endometrium and their regulation throughout the
menstrual cycle. Fertil Steril 2007;87(3):657-63.

[121] Fico A, Maina F, Dono R. Fine-tuning of cell signaling by glypi-

cans. Cell Mol Life Sci 2011;68(6):923-9.

[122] Filmus J, Capurro M, Rast J. Glypicans. Genome Biol

2008;9(5):224.

[104] Borset M, Hjertner O, Yaccoby S, Epstein J, Sanderson RD.

Syndecan-1 is targeted to the uropods of polarized myeloma
cells where it promotes adhesion and sequesters heparin-bind-
ing proteins. Blood 2000;96(7):2528-36.

[123] Capurro MI, Xu P, Shi W, Li F, Jia A, Filmus J. Glypican-3

inhibits Hedgehog signaling during development by com-
peting with patched for Hedgehog binding. Dev Cell
2008;14(5):700-11.

[105] Dhodapkar MV, Sanderson RD. Syndecan-1 (CD 138) in

myeloma and lymphoid malignancies: a multifunctional regu-
lator of cell behavior within the tumor microenvironment.
Leuk Lymphoma 1999;34(1-2):35-43.

[124] Yan D, Lin X. Drosophila glypican Dally-like acts in FGF-

receiving cells to modulate FGF signaling during tracheal mor-
phogenesis. Dev Biol 2007;312(1):203-16.

[125] Song HH, Shi W, Xiang YY, Filmus J. The loss of glypican-3

induces alterations in Wnt signaling. J Biol Chem 2005;280(3):
2116-25.

[106] Anttonen A, Kajanti M, Heikkila P, Jalkanen M, Joensuu H.

Syndecan-1 expression has prognostic signiicance in head and
neck carcinoma. Br J Cancer 1999;79(3-4):558-64. [126] Kirkpatrick CA, Knox SM, Staatz WD, Fox B, Lercher DM,

Selleck SB. The function of a Drosophila glypican does not
depend entirely on heparan sulfate modiication. Dev Biol
2006;300(2):570-82.

[107] Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A,

et al. Soluble syndecan-1 promotes growth of myeloma tumors
in vivo. Blood 2002;100(2):610-7.

[108] Choi S, Lee E, Kwon S, Park H, Yi JY, Kim S, et al.

Transmembrane domain-induced oligomerization is crucial

[127] Haupt LM, Murali S, Mun FK, Teplyuk N, Mei LF, Stein GS,

et al. The heparan sulfate proteoglycan (HSPG) glypican-3